We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.11% | 103.20 | 9,110 | 13:57:46 |
From May 2022 to May 2024
By Kim Richters
Novartis AG's Phase 3 Canopy-A study for canakinumab as adjuvant treatment in non-small cell lung cancer didn't meet the primary endpoint of disease-free survival versus placebo.
The Swiss pharmaceutical company said Monday that it will present findings from the study, which concerned patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer, at an upcoming medical meeting.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
August 15, 2022 01:50 ET (05:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
